Christopher S Henney
CIK 1242880 · Interim CEO and President · last filed 2023-07-03
Christopher S Henney is an Interim CEO and President who has filed 84 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for CYCCP, was dated Jul 3, 2023. Across all open-market trades the lifetime net is −$6.4M, making them a net seller over the disclosed history. 6 SEC filings were submitted jointly with TECHNE CORP /MN/.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PRTA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Bio Green Med Solution, Inc. (CYCCP) Delisted | Director | 39,415 | $5.05 | $199.0K | $0 | 16 | 2023-07-03 |
| PRTA | Director | 0 | $8.47 | $0 | -$6.69M | 21 | 2021-07-16 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 4,725 | — | — | $149.9K | 12 | 2018-01-09 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Interim CEO and President | 60,185 | — | — | $104.0K | 5 | 2017-09-26 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Interim CEO and President | 139,818 | — | — | $0 | 23 | 2016-03-16 |
| Sarepta Therapeutics, Inc. (AVII) Delisted | Director | — | — | — | $0 | 1 | 2009-04-02 |
| SGX PHARMACEUTICALS, INC. (SGXP) Delisted | Director | 0 | — | — | $0 | 5 | 2008-08-21 |
Recent Filings
84 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-07-03 | Bio Green Med Solution, Inc. (CYCCP) Delisted | Grant (A) | +21,219 | $0 | EDGAR |
| 2022-06-16 | Bio Green Med Solution, Inc. (CYCCP) Delisted | Grant (A) | +15,822 | $0 | EDGAR |
| 2021-07-16 | PRTA | Mixed | — | -$490.2K | EDGAR |
| 2021-07-13 | PRTA | Mixed | +177 | -$1.08M | EDGAR |
| 2021-07-12 | PRTA | Mixed | +177 | -$1.08M | EDGAR |
| 2021-06-29 | PRTA | Mixed | — | -$375.7K | EDGAR |
| 2021-06-17 | Bio Green Med Solution, Inc. (CYCCP) Delisted | Grant (A) | +2,374 | $0 | EDGAR |
| 2021-05-21 | PRTA | Grant (A) | — | $0 | EDGAR |
| 2021-02-17 | PRTA | Mixed | — | $0 | EDGAR |
| 2020-06-29 | Bio Green Med Solution, Inc. (CYCCP) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.